Palvella Therapeutics (PVLA) Other Non-Current Assets (2015 - 2023)
Palvella Therapeutics (PVLA) posted quarterly Other Non-Current Assets of $287000.0 for Q3 2023, down 78.04% year-over-year from $1.3 million in Q3 2022, and down 73.74% quarter-over-quarter from $1.1 million in Q2 2023.
Palvella Therapeutics (PVLA) Other Non-Current Assets (2015 - 2023) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Other Non-Current Assets for 9 consecutive years, with $287000.0 the latest figure, recorded in Q3 2023.
- In Q3 2023, Other Non-Current Assets fell 78.04% year-over-year to $287000.0; the TTM figure through Sep 2023 stood at $287000.0 (down 78.04% YoY), while the FY2022 annual figure was $1.4 million, down 52.86% from the prior year.
- Other Non-Current Assets eased to $287000.0 in Q3 2023 per PVLA's latest filing, from $1.1 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $11.5 million in Q2 2019 and bottomed at $287000.0 in Q3 2023.
- Historically, Other Non-Current Assets has averaged $2.9 million across 5 years, with a median of $2.4 million in 2022.
- Annual changes were most pronounced in 2019 — Other Non-Current Assets jumped 8806.98% — and 2020, when it sank 82.81%.
- Palvella Therapeutics' Other Non-Current Assets stood at $3.1 million in 2019, then advanced by 5.18% to $3.3 million in 2020, then dropped by 12.24% to $2.9 million in 2021, then tumbled by 52.86% to $1.4 million in 2022, then plunged by 79.04% to $287000.0 in 2023.
- Business Quant data shows PVLA's Other Non-Current Assets at $287000.0 in Q3 2023, $1.1 million in Q2 2023, and $1.3 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 287,000.00 |
| Jun 30, 2023 | 1.09 Mn |
| Mar 31, 2023 | 1.25 Mn |
| Dec 31, 2022 | 1.37 Mn |
| Sep 30, 2022 | 1.31 Mn |
| Jun 30, 2022 | 2.36 Mn |
| Mar 31, 2022 | 2.67 Mn |
| Dec 31, 2021 | 2.90 Mn |
| Sep 30, 2021 | 2.95 Mn |
| Jun 30, 2021 | 3.12 Mn |
| Mar 31, 2021 | 3.21 Mn |
| Dec 31, 2020 | 3.31 Mn |
| Sep 30, 2020 | 1.99 Mn |
| Jun 30, 2020 | 1.98 Mn |
| Mar 31, 2020 | 1.89 Mn |
| Dec 31, 2019 | 3.15 Mn |
| Sep 30, 2019 | 7.77 Mn |
| Jun 30, 2019 | 11.49 Mn |
| Mar 31, 2019 | 1.87 Mn |
| Dec 31, 2018 | 910,000.00 |